Changes to This Summary (02/10/2012)
The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.
General Information About Pancreatic Cancer
Updated statistics with estimated new cancer cases and deaths for 2012 (cited American Cancer Society as reference 1).
Stage I and II Pancreatic Cancer
Added text to state that investigators, with longer follow-up, reported a significant improvement in overall survival (OS) that favored gemcitabine (cited Neuhaus et al. as reference 17).
Added text to state that the ESPAC-3 trial randomly assigned patients who had undergone complete macroscopic resection to either 6 months of fluorouracil (5-FU) and folinic acid on days 1 to 5 every 28 days or 6 months of gemcitabine on days 1, 8, and 15 every 28 days; the median OS was 23.0 months for patients treated with 5-FU plus folinic acid and 23.6 months for those treated with gemcitabine (cited Neoptolemos et al. as reference 18 and level of evidence 1iiA).
Added text to the list of standard treatment options to include radical pancreatic resection with postoperative chemotherapy (gemcitabine or 5-FU/folinic acid).
Revised text to include radical pancreatic resection with postoperative 5-FU chemotherapy and radiation therapy.
Revised text in the list of treatment options under clinical evaluation to include gemcitabine and capecitabine, gemcitabine and erlotinib, gemcitabine and erlotinib with or without 5-FU/capecitabine-based chemoradiation, and preoperative chemotherapy and/or radiation therapy.
This section was extensively revised.
Added Moore et al. as reference 4.
Added text to state that many phase III studies evaluated a combination regimen with either a platinum analogue (cisplatin or oxaliplatin) or fluoropyrimidine versus single-agent gemcitabine (cited Poplin et al. as reference 5 and Colucci et al. as reference 6).
Added text to state that second-line chemotherapy after progression on a gemcitabine-based regimen may be beneficial, citing a preliminary report of the CONKO-003 trial and use of the 5-FU, leucovorin, and oxaliplatin (OFF) regimen, in which patients receiving OFF had a significant improvement in OS; the OFF regimen was later compared with the same regimen without oxaliplatin in patients refractory to gemcitabine, and was associated with a significant improvement in OS (cited Pelzer et al. as reference 7).
Updated Royal et al. as reference 1.
Back to Top
